May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's second round of Quick Takes on selected abstracts (see "May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven").

Aduro ends MM trial of BION-1301
Aduro Biotech Inc. (NASDAQ:ADRO) discontinued a Phase I/II trial of BION-1301 to treat relapsed or refractory multiple myeloma after reporting no objective responses among 14 evaluable patients. BION-1301 is a humanized IgG4 mAb targeting TNFSF13...